News

New roadmap developed to genetically test for hereditary prostate cancer

A roadmap to help identify which men and their families may benefit from genetic evaluation for inherited prostate cancer has been developed by a team of researchers. To date, there have been few recommendations to guide physicians about when to offer men genetic consultation for prostate cancer risk. Now, an international and inter-specialty panel of experts convened at the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University have developed a comprehensive set of recommendations. This consensus statement, published December 13th in the Journal of Clinical Oncology, will help physicians and stakeholders make sense of a rapidly evolving field of practice. "There is increasing recognition that some prostate cancers can be inherited. Genetic testing could provide men and their families with information about cancer [...]

2018-01-09T08:50:54+00:00 January 9th, 2018|

CMS Announces Increase To ASC Payment For HIFU Prostate Ablation

SonaCare Medical Reports That Medicare recognizes HIFU prostate ablation as a device-intensive procedure driving new ASC payment going into effect on or after October 1, 2017 CHARLOTTE, N.C., Sept. 20, 2017 SonaCare Medical, leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, is pleased to announce an increase in Medicare payment for prostate HIFU ablation in the Ambulatory Surgical Center (ASC) setting. In the October 2017 update of the ASC Payment System, the Centers for Medicare and Medicaid Services (CMS) indicated that the ASC payment status for C9747, the code used to bill for HIFU ablation of prostate tissue, now recognizes HIFU as a "device-intensive procedure". The new typical ASC payment level is $5,444.89, as compared to the approximately $4,000 payment amount which went [...]

2017-12-13T13:37:18+00:00 November 14th, 2017|

Research News: Reduced Risk of Prostate Cancer in Men with Low Testosterone

Men with unusually low amounts of testosterone in their blood are around 20% less likely to develop prostate cancer, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool. Scientists from the University of Oxford conducted the largest analysis of hormones and prostate cancer risk to date. The study – funded by Cancer Research UK – looked at blood samples from around 19,000 men aged 34-76 years, collected between 1959 and 2004. Of these men 6,900 went on to develop prostate cancer. The researchers divided the 19,000 men into ten groups – ranging from men with the lowest amount of testosterone in their blood to those with the highest, and compared their prostate cancer risk. They found that men [...]

2017-12-13T13:37:18+00:00 November 8th, 2017|

New research could lead to reduction in recurrence of prostate cancer

Recurrence of prostate cancer could be reduced thanks to exciting new discovery Ground breaking research could reduce the recurrence of prostate cancer in males, a new study in the journal Nature Communications reports. During this in depth study, an international team of researchers led by British scientists investigated the impact of anti-hormone therapy on samples taken from patients with prostate cancer. Anti-hormone therapy is a commonly prescribed treatment for cancer of the prostate, which helps to reduce the levels of male hormones -- that stimulate cancer cells to grow -- in the gland. Researchers discovered that an inadvertent consequence of anti-hormone therapy treatment is the activation of the DNA repair enzyme, PARP. The triggering of PARP enables cancer cells to withstand anti-hormone therapy treatment, causing [...]

2017-12-13T13:37:18+00:00 October 17th, 2017|

Prostate Cancer News: PSA screening significantly reduces the risk for death

After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. These findings suggest that current guidelines recommending against routine PSA-based screening may be revised. However, questions remain about how to implement screening so that the benefits outweigh the potential harms of over-diagnosis and overtreatment. The findings are published in Annals of Internal Medicine. Current guidelines from the United States Preventive Services Task Force (USPSTF) recommend against prostate-specific antigen (PSA) screening for prostate cancer because the evidence for the test showed very low probability that it would reduce [...]

2017-12-13T13:37:19+00:00 October 11th, 2017|

Dr. Michael Lazar on September’s Prostate Cancer Awareness Campaign; Why Early Detection Saves Lives

Santa Rosa Urologist and Prostate cancer expert Dr. Michael Lazar provides an overview of prostate cancer screening options, and offers insight on a recent study suggesting that early detection saves lives. September is Prostate Cancer Awareness Month helping to put the spotlight on a very important topic; early treatment options. Second only to skin cancer, prostate cancer is the most common cancer among men in the USA and the second most common cause of cancer related death, lung cancer taking the number one spot. Currently it is estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. Why Early Detection is Important A new study out this month by the American College of Physicians revealed that screening in fact reduces [...]

2017-12-13T13:37:19+00:00 September 20th, 2017|

Health Update Interview with Dr. Michael Lazar on iHeartRadio

Dr. Michael Lazar Interview on iHeart Radio Dr. Michael Lazar on HIFU for prostate cancer: In this Interview aired recently on iHeartRadio Dr. Lazar describes the many benefits of HIFU for early diagnosed prostate cancer.  "This is going to be a game-changer, without a doubt," says Dr. Lazar. Listen to the interview by clicking the audio file above. What is High Intensity Focused Ultrasound (HIFU)? HIFU is an FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. However, at the focal point of the sound waves (like a [...]

2017-12-13T13:37:19+00:00 September 19th, 2017|

Dr. Lazar Health Update Interview on iHeartRadio

Dr. Michael Lazar Interview on iHeart Radio Dr. Michael Lazar on HIFU for prostate cancer: In this Interview aired recently on iHeartRadio Dr. Lazar describes the many benefits of HIFU for early diagnosed prostate cancer.  "This is going to be a game-changer, without a doubt," says Dr. Lazar. Listen to the interview by clicking the audio file above. What is High Intensity Focused Ultrasound (HIFU)? HIFU is an FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. However, at the focal point of the sound waves (like a [...]

2017-12-13T13:37:19+00:00 September 19th, 2017|

California HIFU Shares Prostate Cancer Facts for National Prostate Cancer Month

September is National Prostate Cancer Awareness Month. Prostate cancer is the most common type of cancer among men in the US, other than skin cancer.  What are the symptoms of prostate cancer? Early prostate cancer usually causes no symptoms. Men who have prostate cancer can be symptom-free for years. But as it grows, prostate cancer can cause some symptoms. Men should see a health care provider if they: Have to urinate often, especially at night Have trouble starting or stopping urine flow Have a weak or slow urine flow Have blood in the urine or semen Feel frequent pain or stiffness in the lower back, hips, or ribs Conditions other than prostate cancer could cause these symptoms. But the only way to know what’s causing them is [...]

2017-12-13T13:37:19+00:00 September 12th, 2017|